Verve Therapeutics has positive read from NewAmsterdam data, says Stifel

After NewAmsterdam Pharma (NAMS) announced “positive” topline data from the company’s Phase 3 BROADWAY trial evaluating obicetrapib in adult patients with established atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy, Stifel said the data offer insights and differentiation in favor of Verve Therapeutics’ (VERV) VERVE-101/-102 ahead of Phase 1b Heart-2 data for VERVE-102 next year. NewAmsterdam’s “surprisingly positive (albeit exploratory) findings on major adverse cardiovascular events” should be supportive of what VERVE-101/-102 should be able to demonstrate longer term as well, argues the analyst, who has a Buy rating on Verve shares.